Welcome to Richmond Pharmacology
Our reputation has been gained through the successful conduct of over 250 Early Phase Studies over the last 10 years, ranging from testing Anaesthetic agents to Zinamide interaction studies. The specialist areas in which we have really excelled over many years are Adaptive, Thorough-QT, Japanese and Patient Studies – evident in the numerous peer-reviewed papers we have published.
Welcome to Richmond Pharmacology
Our Business Ethos
Our business ethos is unique: Our revenues serve the National Health Service and St George’s University of London, fund basic research, support charities or otherwise are reinvested in the business. Our business is sustainable, adaptive to change and is led by the same specialists who founded the business more than ten years ago.
Our Sponsors
All our sponsors are preferred clients. Richmond Pharmacology’s interaction with its sponsors is personal and truly strategic, generating enhanced value for drug developers and investors.
Our Work
Our work is closely supervised throughout by the same senior specialists sponsors meet during the first consultation or bid defence. Our services span strategic consultancy and concept development through to final reporting, utilising our many years of experience and leading to successful clinical trials with meaningful results.
Read More »
Our Specialist Services
First In Man Studies
Uniquely based with 2 prominent NHS London hospitals and certified by the highest level of Regulatory Accreditation, Richmond Pharmacology are First Time Into Human specialists. RPL's extensive experience means they can offer a broad spectrum of first in man study services. Learn More about our First in Man Studies
Thorough QTc Study Services (TQT Studies)
All our Thorough QT Studies are in collaboration with Professor Camm, Head of Cardiac and Vascular Sciences, St George's University of London, a world renowned opinion leader in cardiological analysis. In-house expertise and experience makes Richmond Pharmacology the ideal partner for performing definitive QTc Study Solutions. Read more about our Thorough Qt Studies
Bridging Studies
We're the leading global provider of Japanese Bridging Studies. We have succesfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan. Take a look at our Bridging Studies
Patient Recruitment
Our in-house Volunteer and Patient Recruitment department is the largest of any early phase CRO in the UK. We have extensive experience in recruiting a multitude of volunteer panels. Learn more about our Patient Recruitment
Adaptive Study Design
Established as Europe's industry leaders and backed by the support of a highly experienced team of clinical pharmacologists, project managers, a world-class Scientific Advisory Board and a wide range of on-site therapeutically aligned experts, RPL is perfectly equipped for the conduct of complex studies requiring the application of the Adaptive Study Design model in, but not limited to; FTIH, TQT, Japanese and Bridging Studies.
Learn more about adaptive design for early phase clinical trials»
Cardiac Safety Studies
As the leading specialist in Cardiac Safety Study Solutions, we know how important the quality of ECG data, speed and regulatory compliance is to our sponsors. It’s no surprise that Richmond Pharmacology’s Cardiac Safety Studies are trusted worldwide.
Learn more about our Cardiac Safety Studies »
Early Phase Studies
Our reputation has been gained through the successful conduct of over 250 Early Phase Studies since 2001. Our experience spans simple BE studies to complex FTIH studies. Our hospital integrated Phase I unit provides an optimum safety environment for Early Phase Studies »
Our Featured Publications
- Rule Brittania – the advantages of conducting first-time-in-human (FTIH) studies in the UK compared to other European markets.
- Levofloxacin can be used as a positive control in QT/QTc studies in healthy subjects (paper).
- An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole.
- SKY0402 (bupivacaine) does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers.
- Lamotrigine does not prolong QTc in TQT studies in healthy subjects.
- TQT Studies: Their Impact on Drug Development and the Key Elements of a Successful TQT Study
- Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain.
- Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously.
Click here to view all of Richmond Pharmacology's Publications and Book Chapters
Richmond Pharmacology's people have extensive knowledge and expertise.
WE RISE TO THE CHALLENGE
We know we can help your
business. We always rise
to the challenge…
Challenge Us